Business Context and Reporting Period
Bullfrog AI Holdings, Inc. (BFRG) filed a Form 8-K on March 27, 2026, reporting the entry into a material definitive agreement. The Company is an emerging growth company incorporated in Nevada, with its principal executive offices in Gaithersburg, MD. Its common stock and tradeable warrants trade on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain audited financial statements, revenue figures, profit data, cash flow statements, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Agreement Details
On March 27, 2026, the Company entered into a one-year Feasibility Agreement with a global pharmaceutical company (the "Client"). Key terms include:
- Scope: The Company will utilize its proprietary bfLEAP® AI and machine learning tool to identify prioritized drug target candidates, causal gene networks, and target dossiers for major depressive disorder (MDD).
- Compensation: The Company is eligible for pre-determined milestone payments upon delivery of specific deliverables.
- Exclusivity Option: The Client holds an option to secure exclusive rights to use a selected "final target" drug candidate for research and development for three years.
- Termination: The Client may terminate without cause with 30 days' notice. Either party may terminate immediately for uncured breaches after a 30-day cure period.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or specific management commentary on future earnings. The primary risk associated with this agreement is the Client's ability to terminate the contract without cause upon 30 days' notice, which could impact the realization of milestone payments. Additionally, the agreement is subject to customary representations, warranties, and confidentiality provisions.
Investor Verification Checklist
- Verify the identity of the "global pharmaceutical company" (Client) as it is not named in the filing.
- Review the redacted Exhibit 10.1 to understand the specific value of the pre-determined milestone payments.
- Assess the Company's current cash runway to determine if it can sustain operations while awaiting milestone payments.
- Monitor the press release (Exhibit 99.1) for any additional details on the commercial potential of the MDD targets.